Other Key Trials in the Treatment of BCG-Unresponsive High-Risk NMIBC

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral resection of bladder tumors.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder cancer, enabling bladder preservation.

UGN-102 shows promising results in treating recurrent low-grade, intermediate-risk bladder cancer, with high response rates and manageable side effects.